DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Lawitz E, Rodriguez-Torres M, Muir A. et al.
28 days of the hepatitis C protease inhibitor VX-950, in combination with peg-interferon-alfa-2a and ribavirin, is well-tolerated and demonstrates robust antiviral effects
Gastroenterology 2006; 130(suppl 2): A686-
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.